“Lipodystrophy – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lipodystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Lipodystrophy: Overview Lipodystrophy refers to medical problem where there is an abnormal distribution of fat in the body. The disease may be inherited genetically, (for example, familial partial lipodystrophy or FPLD), or acquired. If inherited it may be present at birth (congenital). There are five types of lipodystrophy: Congenital generalized lipodystrophy, acquired generalized lipodystrophy, Acquired partial lipodystrophy, High active antiretroviral therapy-induced lipodystrophy, and Localized lipodystrophy. The specific symptoms present, severity, and prognosis can vary greatly depending upon the specific type of lipodystrophy and the presence and extent of associated symptoms. To make the medical diagnosis of lipodystrophy the doctor first examine the abnormal appearance caused by changes in fat loss or gain, and then he or she generally look for the characteristic clinical symptoms and signs.
"Lipodystrophy - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lipodystrophy pipeline landscape is provided which includes the disease overview and Lipodystrophy treatment guidelines. The assessment part of the report embraces, in depth Lipodystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lipodystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Lipodystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Lipodystrophy.
Lipodystrophy Emerging Drugs Chapters This segment of the Lipodystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lipodystrophy Emerging Drugs • Volanesorsen (IONIS-APOCIII-LRx): Ionis Pharmaceuticals
IONIS-APOCIII-LRx, formerly known as AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III, for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. The drug is currently being investigated in Phase III stage of development for the treatment of patients with Hyperlipoproteinaemia; Lipodystrophy. The drug has also been granted the Orphan drug designation by U.S FDA and European Medicines Agency.s
• Vupanorsen: Pfizer
Vupanorsen is an investigational antisense therapy, discovered by Ionis Pharmaceuticals and co-developed by Ionis and its subsidiary Akcea Therapeutics. Vupanorsen has been developed using Ionis’ advanced LIgand Conjugated Antisense (LICA) technology platform to inhibit the production of angiopoietin-like 3 (ANGPTL3) protein, which an important regulator of triglyceride and cholesterol metabolism in the liver. Pfizer has commenced a Phase 2b study of vupanorsen, in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs).
Further product details are provided in the report……..
Lipodystrophy: Therapeutic Assessment This segment of the report provides insights about the different Lipodystrophy drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Lipodystrophy
There are approx. 10+ key companies which are developing the therapies for Lipodystrophy. The companies which have their Lipodystrophy drug candidates in the most advanced stage, i.e. Phase III include, ContraFect.
This report covers around 10+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Lipodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Lipodystrophy: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lipodystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lipodystrophy drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Lipodystrophy drugs?
• How many Lipodystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lipodystrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lipodystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Lipodystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?
Our reports have been used by over 10K customers, including:
278 pages •
By Global Industry Analysts
• Apr 2021
- Global Anatomic Pathology Market to Reach $26.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Anatomic Pathology estimated at US$18.7 Billion in the year 2020, is projected to reach a revised size of US$26.3 Billion by 2027, growing at a CAGR of 4.9% over the analysis period 2020-2027....
Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They also provide required nutrients to the patients suffering from diabetes, cancer and other diseases. Intravenous solutions...
Melanoma - Epidemiology Forecast to 2029
Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin (World Health Organization, 2017).Melanocytes are embryological derivatives of neural crest tissue, and...
573 pages •
By Global Industry Analysts
• Apr 2021
- Looking Beyond Today’s Challenges to Tomorrow’s Healthcare Needs. Genetic Testing to Reach $18.9 Billion as the Burden of Non-Communicable Diseases Grows Bigger
- The global market for Genetic Testing is forecast to reach US$18.9 billion by the year 2027, trailing a post COVID-19 CAGR of 8.6% over the...
185 pages •
By Global Industry Analysts
• Apr 2021
- Global Pathology Instruments Market to Reach $4.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Pathology Instruments estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$4.3 Billion by 2027, growing at a CAGR of 5.2% over the analysis period 2020-2027....
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Global Magnetic Beads Market size is expected to reach $2 billion by 2026, rising at a market growth of 12.7% CAGR during the forecast period. Magnetic beads refer to a tool, which is made up of small particles of iron oxides like magnetite that provide superparamagnetic properties to these beads. They do not attract one another when they...
120 pages •
By Infiniti Research Limited
• Mar 2021
Global Pathology Instruments Market 2021-2025 The analyst has been monitoring the pathology instruments market and it is poised to grow by $ 1.23 bn during 2021-2025 progressing at a CAGR of 6% during the forecast period. Our report on pathology instruments market provides a holistic analysis, market size and forecast,...
200 pages •
By The Business Research Company
• Mar 2021
Major players in the ultra-low temperature freezers market are Arctiko, Eppendorf, Esco Micro Pte Ltd, Haier, Helmer Scientific, Bionics Scientific Technologies (P). Ltd, PHC Holdings Corporation, Labcold Ltd, Remi Group, and Stirling Ultracold. The global ultra-low temperature freezers market is expected to decline from $633.94 million...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.